Health Economics and Outcomes Research, BeOne Medicines Ltd., San Carlos, CA, USA.
Citations 2
Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia
Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US)
Expert Review of Hematology | January 13, 2026 | Volume: 19 | Issue: 3 | Pages: 321-331